PR86682

TOKYO and HYDERABAD, India, Nov. 17 /PRNewswire=KYODO JBN/--

- Participating in the PharmaLab Expo Tokyo during Nov 25-27 to jumpstart outreach

    Sai Life Sciences, one of India's fastest growing Contract Research,

Development & Manufacturing Organizations [https://www.sailife.com/?utm_source=pr&utm_medium=web&utm_campaign=opens-repres

entative-office-in-japan ] (CRO-CDMO), announced the opening of its

representative office in Tokyo, Japan. The new office will serve as base for

the company's outreach to innovator pharmaceutical and biotech companies in

Japan and other countries in the Asia Pacific region. A seasoned industry

specialist, Mr. Junjiro Sato has been appointed as Representative Director to

be based in Tokyo and spearhead the efforts.

    Sai Life Sciences will be participating in the PharmaLab Expo Tokyo (held

inside INTERPHEX Week) during Nov 25-27, 2020 to create awareness about its

unique service offerings across drug discovery, development and

commercialization.

    Sai Life Sciences already has a significant connection with the Japanese

market. It was the launch site for commercial API supplies of an NCE to Japan

and has supplied over 10 tonnes of API with batch sizes of 50 Kg to 150 Kg

scale over the past 4 years. It also is a supplier of registered starting

materials for two other commercial APIs. From a Discovery perspective, the

company has helped several biotech and pharma companies advance programs from

HIT to lead optimization/ candidate stage, through its chemistry, biology and

DMPK services.  

    Over the past two decades, Sai Life Sciences has served a diverse set of

NCE development programmes, consistently delivering value based on its quality

and responsiveness. It has a 100% successful track record of regulatory

inspections across its R&D and manufacturing facilities from both FDA and PMDA.

Today, it works with 7 of the top 10 large pharma companies, in addition to

several small and mid-sized pharma & biotech companies. It has over 2000

employees across its facilities in India, UK and USA.

    Coinciding with its 20th anniversary in 2019, the company announced Sai

Nxt, an organisation-wide initiative aimed at transforming itself into a new

generation CRO-CDMO. Guided by insights and feedback from customers, it is

investing over US$150M to significantly expand and upgrade its R&D and

manufacturing facilities, deepen scientific capabilities, strengthen automation

and data systems, and above all raise the bar for safety, quality and customer focus.

    About Sai Life Sciences

    Sai Life Sciences is a full-service CRO/ CDMO

[https://www.sailife.com/?utm_source=pr&utm_medium=web&utm_campaign=opens-representative-office-in-japan ] driven by a vision to support the launch of 25 new

medicines by 2025. It works with innovator pharma and biotech companies

globally, accelerating the discovery, development and manufacture of complex

small molecules. A pure-play CDMO, Sai Life Sciences has served a diverse set

of NCE development programs, consistently delivering value based on its quality

and responsiveness. Today, it works with 7 of the top 10 large pharma

companies, as well as several small and mid-sized pharma & biotech companies.

Sai Life Sciences is privately held and backed by global investors, TPG Capital

and HBM Healthcare Investments. https://www.sailife.com 

   Photo: https://mma.prnewswire.com/media/1336500/Junjiro_Sato_Sai_Life_Sciences.jpg 

   Logo: https://mma.prnewswire.com/media/1044186/Sai_Life_Sciences_Logo.jpg 

   Source: Sai Life Sciences